ChemDiv and Berlex Announce Collaboration
March 10 2006 - 9:00AM
PR Newswire (US)
SAN DIEGO, March 10 /PRNewswire/ -- ChemDiv, Inc., a global
chemistry-driven contract research organization, announced today
that it has entered into a discovery research collaboration with
Berlex Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR;
FSE: SCH). The partners will work on the discovery of potential new
lead compounds against several selected GPCR targets. Under the
terms of the collaboration, ChemDiv will apply its integrated
synthetic and medicinal chemistry capabilities and collaborate with
Berlex's scientists in the search for new disease therapies.
Financial terms were not disclosed. "We are looking forward to the
opportunity to work with Berlex and view this as further validation
of our discovery chemistry expertise. ChemDiv's integrated drug
discovery capabilities provide an excellent fit for Berlex and we
hope that our collaborative relationship will be a long-standing
one," said Alexander Kiselyov, Executive VP of R&D at ChemDiv,
Inc. About ChemDiv, Inc. ChemDiv, Inc. (ChemDiv) is a global
chemistry-driven contract research organization focused on the
delivery of new scientific innovation, products and services that
meet the drug discovery needs of its partners. ChemDiv provides
partners with access to Discovery outSource(TM), a full service
drug discovery capabilities encompassing: medicinal chemistry;
pre-clinical development; synthetic chemistry; diverse and focused
screening libraries, as well as global logistics. For additional
information, please visit http://www.chemdiv.com/. About Berlex,
Inc. Committed to addressing unmet medical needs, Berlex, Inc., a
US affiliate of Schering AG, Germany (NYSE:SHR), develops and
markets diagnostic imaging agents, treatments in the areas of
female health care and dermatology, as well as specialized
therapeutics for life-threatening and disabling diseases in the
fields of the central nervous and cardiovascular systems, oncology,
and gastroenterology. Berlex has business operations in New Jersey,
California and Washington. For more information, please visit
http://www.berlex.com/. DATASOURCE: ChemDiv, Inc.; Berlex Inc.
CONTACT: Rouslan Michtchenko, Director Business Development of
ChemDiv, Inc., +1-858-794-4860, or fax, +1-858-794-4931, Web site:
http://www.chemdiv.com/ http://www.berlex.com/
Copyright